Attached files

file filename
EX-31.2 - Vilacto Bio Inc.ex31-2.txt
EXCEL - IDEA: XBRL DOCUMENT - Vilacto Bio Inc.Financial_Report.xls
EX-31.1 - Vilacto Bio Inc.ex31-1.txt
EX-32.1 - Vilacto Bio Inc.ex32-1.txt

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q

(Mark One)
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

                       For the quarter ended June 30, 2014

                                       OR

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
    ACT OF 1934

         For the transition period from _____________ to ______________

                        Commission File Number 000-55023


                                   ZLATO INC.
             (Exact name of registrant as specified in its charter)

           Nevada                                                46-3883208
(State or other jurisdiction of                               (I.R.S. Employer
 Incorporation or organization)                              Identification No.)

                   Mlynska 28, 040 01 Kosice, Slovak Republic
               (Address of principal executive offices) (Zip Code)

        Registrant's telephone number, including area code: 646-875-5747

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding 12 months (or for such  shorter  period that the  registrant  was
required  to file  such  reports),  and  (2) has  been  subject  to such  filing
requirements for the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the registrant has submitted  electronically  and
posted on its corporate Web site, if any, every  Interactive  Data File required
to be submitted and posted pursuant to Rule 405 of Regulation S-T (ss.232.405 of
this chapter)  during the  preceding 12 months (or for such shorter  period that
the registrant was required to submit and post such files). YES [X] NO [ ]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
the definitions of "large accelerated  filer,"  "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ]                        Accelerated filer [ ]

Non-accelerated filer [ ]                          Smaller reporting company [X]

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [X] No [ ]

Number of shares  outstanding of the registrant's  class of common stock as July
15, 2014: 6,000,000

Authorized share capital of the registrant:  75,000,000 common shares, par value
of $0.001

The Company recorded $nil sales revenue for the quarter ended June 30, 2014.

FORWARD-LOOKING STATEMENTS THIS QUARTERLY REPORT ON FORM 10-Q CONTAINS PREDICTIONS, PROJECTIONS AND OTHER STATEMENTS ABOUT THE FUTURE THAT ARE INTENDED TO BE "FORWARD-LOOKING STATEMENTS" WITHIN THE MEANING OF SECTION 21E OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED (COLLECTIVELY, "FORWARD-LOOKING STATEMENTS"). FORWARD-LOOKING STATEMENTS INVOLVE RISKS AND UNCERTAINTIES. A NUMBER OF IMPORTANT FACTORS COULD CAUSE ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE IN THE FORWARD-LOOKING STATEMENTS. IN ASSESSING FORWARD-LOOKING STATEMENTS CONTAINED IN THIS QUARTERLY REPORT ON FORM 10-Q, READERS ARE URGED TO READ CAREFULLY ALL CAUTIONARY STATEMENTS - INCLUDING THOSE CONTAINED IN OTHER SECTIONS OF THIS QUARTERLY REPORT ON FORM 10-Q. AMONG SAID RISKS AND UNCERTAINTIES IS THE RISK THAT THE COMPANY WILL NOT SUCCESSFULLY EXECUTE ITS BUSINESS PLAN, THAT ITS MANAGEMENT IS ADEQUATE TO CARRY OUT ITS BUSINESS PLAN AND THAT THERE WILL BE ADEQUATE CAPITAL OR THEY MAY BE UNSUCCESSUFL FOR TECHNICAL, ECONOMIC OR OTHER REASONS. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. PART I - FINANCIAL INFORMATION ITEM 1. FINANCIAL STATEMENTS Page Number ----------- Balance Sheets ................................................ 3 Statements of Operations ...................................... 4 Statements of Stockholders' Deficit ........................... 5 Statements of Cash Flows ...................................... 6 Notes to the Financial Statements ............................. 7 2
ZLATO INC. (A Development Stage Company) BALANCE SHEETS June 30, 2014 March 31, 2014 ------------- -------------- (unaudited) ASSETS Current assets Cash and bank accounts $ 9,396 $ 13,598 Prepaid office rent 377 -- -------- -------- Total current assets 9,773 13,598 -------- -------- Total assets $ 9,773 $ 13,598 ======== ======== LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities Accounts payable $ 1,020 $ 100 -------- -------- Total current liabilities 1,020 100 -------- -------- Stockholders' equity (Note 4,5) Authorized: 75,000,000 common shares Par value $0.001 Issued and outstanding: 6,000,000 common shares 6,000 6,000 Additional paid-in capital 59,000 59,000 Deficit accumulated during the development stage (56,247) (51,502) -------- -------- Total stockholders' equity 8,753 13,498 -------- -------- Total liabilities and stockholders' equity $ 9,773 $ 13,598 ======== ======== The accompanying notes are an integral part of these financial statements. 3
ZLATO INC. (A Development Stage Company) STATEMENTS OF OPERATIONS (unaudited) Date of Three Months Three Months Incorporation on Ended Ended February 25, 2013 to June 30, 2014 June 30, 2013 June 30, 2014 ------------- ------------- ------------- REVENUE $ -- $ -- $ -- ---------- ---------- ---------- OPERATING EXPENSES General & administrative 1,245 535 11,549 Organization -- -- 555 Professional fees 3,500 6,000 44,143 ---------- ---------- ---------- Loss before income taxes (4,745) (6,535) (56,247) Provision for income taxes -- -- -- ---------- ---------- ---------- Net loss $ (4,745) $ (6,535) $ (56,247) ========== ========== ========== Basic and diluted loss per common share (1) ========== ========== ========== Weighted average number of common shares outstanding (Note 5) 6,000,000 5,000,000 ========== ========== ---------- (1) less than $0.01 The accompanying notes are an integral part of these financial statements. 4
ZLATO INC. (A Development Stage Company) STATEMENTS OF STOCKHOLDERS' EQUITY (unaudited) Deficit Accumulated Common Stock Additional During the Total ------------------- Paid in Development Stockholders' Shares Amount Capital Stage Equity ------ ------ ------- ----- ------ Inception, February 25, 2013 -- $ -- $ -- $ -- $ -- Initial capitalization, sale of common stock to Director on February 25, 2013 5,000,000 5,000 10,000 -- 15,000 Net loss for the period -- -- -- (555) (555) --------- ------- -------- -------- ------- Balance March 31, 2013 5,000,000 5,000 10,000 (555) 14,445 Common stock issued for cash 1,000,000 1,000 49,000 -- 50,000 Net loss for the period -- -- -- (50,947) (50,947) --------- ------- -------- -------- ------- Balance March 31, 2014 6,000,000 6,000 59,000 (51,502) 13,498 Net loss for the period -- -- -- (4,745) (4,745) --------- ------- -------- -------- ------- Balance June 30, 2014 6,000,000 $ 6,000 $ 59,000 $(56,247) $ 8,753 ========= ======= ======== ======== ======= The accompanying notes are an integral part of these financial statements. 5
ZLATO INC. (A Development Stage Company) STATEMENTS OF CASH FLOWS (unaudited) Date of Three Months Three Months Incorporation on Ended Ended February 25, 2013 to June 30, 2014 June 30, 2013 June 30, 2014 ------------- ------------- ------------- OPERATING ACTIVITIES Net loss for the period $ (4,745) $ (6,535) $(56,247) Changes in operating assets and liabilities: Prepaid office rent (377) (355) (377) Accounts payable 920 417 1,020 -------- -------- -------- Net cash used for operating activities (4,202) (6,473) (55,604) -------- -------- -------- FINANCING ACTIVITIES Proceeds from issuance of common stock -- -- 65,000 -------- -------- -------- Net cash provided by financing activities -- -- 65,000 -------- -------- -------- Increase (decrease) in cash during the period (4,202) (6,473) 9,396 Cash, beginning of the period 13,598 14,445 -- -------- -------- -------- Cash, end of the period $ 9,396 $ 7,972 $ 9,396 ======== ======== ======== Supplemental disclosure with respect to cash flows: Cash paid for income taxes $ -- $ -- $ -- Cash paid for interest $ -- $ -- $ -- The accompanying notes are an integral part of these financial statements. 6
ZLATO INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS June 30, 2014 (unaudited) NOTE 1. GENERAL ORGANIZATION AND BUSINESS The Company was originally incorporated under the laws of the state of Nevada on February 25, 2013. The Company is devoting substantially all of its present efforts to establish a new business. It is considered a development stage company, and has had no revenues from operations to date. Initial operations have included organization and capital formation. Management is planning to develop and then market electronic medical record software for small to medium sized physician offices and clinics. NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES ACCOUNTING BASIS The accounting and reporting policies of the Company conform to U.S. generally accepted accounting principles applicable to development stage enterprises. In the opinion of management, all adjustments considered necessary for fair presentation have been included in the financial statements. All losses accumulated since inception has been considered as part of the Company's development stage activities. DEVELOPMENT STAGE COMPANY The accompanying financial statements have been prepared in accordance with generally accepted accounting principles related to development-stage companies. A development-stage company is one in which planned principal operations have not commenced or if its operations have commenced, there has been no significant revenues there from. BASIS OF PRESENTATION The financial statements of the Company have been prepared using the accrual basis of accounting in accordance with generally accepted accounting principles in the United States of America and are presented in U.S. dollars. The Company has adopted a March 31 fiscal year end. 7
ZLATO INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS June 30, 2014 (unaudited) NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) EARNINGS PER SHARE The basic earnings (loss) per share is calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares during the year. The diluted earnings (loss) per share is calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity. The Company has not issued any options or warrants or similar securities since inception. DIVIDENDS The Company has not yet adopted any policy regarding payment of dividends. No dividends have been paid during the periods shown. CASH The Company's cash consists of funds deposited with its lawyer into the law firm's trust account. FOREIGN CURRENCY TRANSLATION The Company has adopted the US dollar as its functional and reporting currency because most of its transactions are denominated in US currency. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company estimates the fair value of financial instruments using the available market information and valuation methods. Considerable judgment is required in estimating fair value. Accordingly, the estimates of fair value may not be indicative of the amounts the Company could realize in a current market exchange. INCOME TAXES A deferred tax asset or liability is recorded for all temporary differences between financial and tax reporting and net operating loss carryforwards. Deferred tax expense (benefit) results from the net change during the year of deferred tax assets and liabilities. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of the deferred tax assets, will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. 8
ZLATO INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS June 30, 2014 (unaudited) NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED) REVENUE RECOGNITION The Company will recognize revenue when products are fully delivered or services have been provided and collection is reasonably assured. USE OF ESTIMATES The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. RECENT ACCOUNTING PRONOUNCEMENTS The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on the Company's results of operations, financial position or cash flow. NOTE 3. GOING CONCERN The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has net losses from the date of incorporation on February 25, 2013 to June 30, 2014 of $56,247. The Company intends to fund its expenditures through equity financing arrangements, which may be insufficient to fund its proposed development expenditures, working capital and other cash requirements through the next fiscal year ending March 31, 2015. The ability of the Company to emerge from the development stage and continue as a going concern is dependent upon the Company's successful efforts to raise sufficient capital for its business plans and then attaining profitable operations. In response to these issues, management has planned the following actions: - The Company is attempting to raise additional equity funds through private placement to commercialize its product. - Management is currently formulating plans to develop and sell electronic medical records software to generate future revenues. There can be no assurances, however, that management's expectations of future revenues will be realized. 9
ZLATO INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS June 30, 2014 (unaudited) NOTE 3. GOING CONCERN (CONTINUED) Over the next 12 months, management estimates the minimum amount of additional funding necessary to enable the Company to remain viable is a minimum of $15,000 and approximately $200,000 to fully carry out its intended business plan. These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty. NOTE 4. STOCKHOLDERS' EQUITY AUTHORIZED The Company is authorized to issue 75,000,000 shares of $0.001 par value common stock. All common stock shares have equal voting rights, are non-assessable and have one vote per share. Voting rights are not cumulative and, therefore, the holders of more than 50% of the common stock could, if they choose to do so, elect all of the directors of the Company. ISSUED AND OUTSTANDING On February 25, 2013 (inception), the Company issued 5,000,000 shares of its common shares to its President, Secretary Treasurer and Director for cash of $.003 per share or$15,000 in aggregate. See Note 5. On September 30 and October 31, 2013 the Company accepted subscriptions under its registered offering for 1,000,000 shares of common stock for cash of $0.05 per share or aggregate proceeds of $50,000. NOTE 5. RELATED PARTY TRANSACTIONS The Company's officer and director is involved in other business activities and may, in the future, become involved in other business opportunities. If a specific business opportunity becomes available, such persons may face a conflict in selecting between the Company and their other business interests. The Company has not formulated a policy for the resolution of such conflicts. On February 25, 2013, the Company issued 5,000,000 shares of its common stock to its President, Secretary Treasurer and Director for cash of $15,000. See Note 4. NOTE 6. INCOME TAXES Net deferred tax assets are $0. Realization of deferred tax assets is dependent upon sufficient future taxable income during the period that deductible temporary differences and carry-forwards are expected to be available to reduce taxable income. As the achievement of required future taxable income is uncertain, the Company recorded a 100% valuation allowance. Management believes it is likely that any deferred tax assets will not be realized. 10
ZLATO INC. (A Development Stage Company) NOTES TO FINANCIAL STATEMENTS June 30, 2014 (unaudited) NOTE 6. INCOME TAXES (CONTINUED) As of March 31, 2014, the Company had a net operating loss carry forward of approximately $51,502, of which $555 will expire by March 31, 2033 and $50,947 will expire by March 31, 2034. NOTE 7. SUBSEQUENT EVENTS We have evaluated subsequent events through to the date of issuance of the financial statements, and did not have any material recognizable subsequent events after June 30, 2014 11
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following information should be read in conjunction with our financial statements and related notes appearing elsewhere in this Form 10-Q, together with the more detailed business information and the March 31, 2014 audited financial statements included in the Company's Annual Report on Form 10K (File No. 000-55023), as filed with the SEC on June 2, 2014. It also includes our detailed expenditures and milestones for our plan of operations described herein. Statements in this section and elsewhere in this Form 10-Q that are not statements of historical or current fact constitute "forward-looking" statements. GENERAL OVERVIEW Our Company was incorporated in the State of Nevada on February 25, 2013 to engage in the development and sale of electronic medical record ("EMR") software for small and medium sized physician offices and clinics. Our principal executive offices are located at Mlynska 28, 040 01 Kosice, Slovak Republic. Our phone number is (646) 875-5747. We are a development stage company, we only just completed our first fiscal year end on March 31 and we have no subsidiaries. Our common shares are posted on the OTCBB under the symbol "ZFLO". During the year ended March 31, 2014, we completed development of our basic EMR software and launched our website. You can view the website and register to view and use our EMR software at www.zlatoinc.com. Our basic EMR software collects and captures patient data electronically, and stores it in a format that enables efficient access and viewing, and distribution by printing or email. Our planned second phase product development will focus on interconnectivity of our EMR software with various third party vital signs monitors, such as blood pressure monitors or temperature monitors. We currently have no revenues, no operating history, and no users or revenues for our software. Our plan of operations over the next 12 month period is to raise an additional $200,000 for an adequate marketing program to launch our product, and $50,000 to further develop our software over an 8-10 month period to interface with third party diagnostic and vital signs monitor equipment suppliers. We cannot guarantee we will be successful in doing so or with planned our business operations. Our business is subject to all of the risks inherent in the establishment of a new business enterprise and revenue generation from our basic EMR software product is dependent on additional financing of approximately $200,000 for commercial launch, and $50,000 to develop the software development kit for interoperability with third parties. Our current funds are sufficient to allow us to operate for the next 3-6 months, and we currently estimate that we will need an additional $5-10,000 just to maintain our corporate existence and meet our regulatory requirements over the next 12 months. GOING CONCERN We have very limited operations and no revenues. We have incurred losses from operations since inception. No revenues are anticipated until we complete and successfully commercialize our planned EMR software. The ability of our Company to continue as a going concern is dependent on raising capital to fund our business plan and ultimately to attain profitable operations. Accordingly, these factors raise substantial doubt as to the Company's ability to continue as a going concern. Our activities to date have been financed from the proceeds of share subscriptions. From our inception to June 30, 2014 we have raised a total of $65,000 in gross proceeds from the issuance of our common stock. We require significant additional financing to develop our business. There is no guarantee that we will be able to raise any additional funds. 12
PLAN OF OPERATION Our long term business objectives are: * Achieve ongoing profitability from the sale of our products and create value for our stockholders, users and clients. * Become a well-recognized brand for easy to use, cost effective EMR software and connectivity to third party diagnostic equipment * Develop a leadership role over time in our specialty. We cannot guarantee we will be successful in our business operations. Our business is subject to all of the risks inherent in the establishment of a new business enterprise and we are a number of months away from generating any revenue, if at all. 12 MONTH PLAN OF OPERATION Our plan of operations over the next 12 month period is focused exclusively on raising additional capital for the commercial launch of our basic EMR software and development of an interoperability kit with third party monitoring equipment. We currently estimate we will require and additional $200,000 for the commercial launch of our basic EMR software and another 8-10 months and $50,000 to develop the software development kit for interoperability with third parties. We do not have any arrangements in place for this additional financing. Our commercial launch budget also includes approximately $20,000 for the development of an automated software deployment system which will enable us to either run the software for licensed users on our servers, or sell our software to clients via the internet. Fixes and updates can also be easily deployed through this system, ensuring that all of our clients are running on the latest version. We also plan to hire a contract sales consultant at a monthly cost of $3,000. His or her initial responsibilities will focus on the selection of several beta test clients to test our software prior to commercial sale. Ms. Gallovicova is responsible for all financing activities, and developing all job specifications for our third party contract software developers or firms. She will also be responsible for hiring the sales consultant, and will oversee the sales consultant in their role specifically as beta test subjects are selected and the marketing plan is developed. Without additional financing on a timely basis, our business will fail. RESULTS OF OPERATIONS We incurred a loss of $4,745 and $6,535 for the three month periods ended June 30, 2014 and 2013 respectively. This loss includes $1,245 for general and administrative costs (2013 - $535) and $3,500 (2013 - $6,000) for professional fees. From inception on February 25, 2013 to June 30, 2014 we have incurred cumulative losses of $56,247. We believe we will continue to incur losses into the foreseeable future as we develop our business. REVENUES We did not generate any revenues from February 25, 2013 (inception) to June 30, 2014. Future revenue generation is dependent on obtaining the necessary financing to commercially launch our product. LIQUIDITY AND CAPITAL RESOURCES Historically, we have financed our cash flow and operations solely from the sale of $65,000 of common stock. Of the $65,000 we have raised since inception, $55,604 was used for operating activities since our inception on February 25, 2013. As of June 30, 2014, our resultant cash balance was $9,396 and our net working capital balance was $8,753. We believe our current cash and net working capital balance is sufficient to cover our plan of operations for the next 3-6 months, none of which can be used to commercialize our EMR software. We must raise significant additional funding 13
to continue with our business. We believe we will require an additional $5-10,000 just to maintain our existence for the balance of the fiscal year and $200,000 for marketing expenses for the commercial launch of our basic EMR software. We also require another 8-10 months and $50,000 to develop the software development kit for interoperability with third party monitoring equipment manufacturers. These funds will have to be raised through equity financing, debt financing, or other sources, which may result in the dilution in the equity ownership of our shares. We will also need more funds if the costs of commercialization and further development are greater than we have budgeted. We will also require additional financing to sustain our business operations if we are ultimately not successful in earning revenues. We currently do not have any arrangements in place regarding our current offering or any subsequent offering for further financing and we may not be able to obtain financing when required. Obtaining commercial loans, assuming those loans would be available, will increase our liabilities and future cash commitments. There are no assurances that we will be able to obtain further funds required for our continued operations. Even if additional financing is available, it may not be available on terms we find favorable. At this time, there are no anticipated sources of additional funds in place. Failure to secure the needed additional financing will have an adverse effect on our ability to remain in business. ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 3. ITEM 4. CONTROLS AND PROCEDURES DISCLOSURE CONTROLS AND PROCEDURES Under the supervision and with the participation of our management, including our principal executive officer and the principal financial officer, we are responsible for conducting an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as of the end of the fiscal period covered by this report. Disclosure controls and procedures means that the material information required to be included in our Securities and Exchange Commission ("SEC") reports is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms relating to our company, including any consolidating subsidiaries, and was made known to us by others within those entities, particularly during the period when this report was being prepared. Based on this evaluation, our principal executive officer and principal financial officer concluded as of the evaluation date that our disclosure controls and procedures were effective as of June 30, 2014. CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING There were no changes in our internal controls over financial reporting that occurred during the period covered by this report, which has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 14
PART II - OTHER INFORMATION ITEM 1. LEGAL PROCEEDINGS None. ITEM 1A. RISK FACTORS As a smaller reporting company (as defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information called for by this Item 1A. ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS None. ITEM 3. DEFAULTS UPON SENIOR SECURITIES None. ITEM 4. MINE SAFETY DISCLOSURES Not applicable. ITEM 5. OTHER INFORMATION None. ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K Pursuant to Rule 601 of Regulation SK, the following exhibits are included herein or incorporated by reference. Exhibit Number Description ------ ----------- 3.1 Articles of Incorporation* 3.2 By-laws* 31.1 Certification Pursuant to 18 U.S.C. ss. 1350, Section 302 31.2 Certification Pursuant to 18 U.S.C. ss. 1350, Section 302 32.1 Certification Pursuant to 18 U.S.C. ss.1350, Section 906 101 Interactive Data Files pursuant to Rule 405 of Regulation S-T ---------- * Incorporated by reference to our S-1 Registration Statement, File 333-188610, filed on May 15, 2013 Reports on Form 8-K None. 15
SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on this 16th day of July 2014. ZLATO INC. Date: July 16, 2014 By: /s/ Dana Gallovicova ----------------------------------------- Name: Dana Gallovicova Title: President, CEO, Secretary Treasurer Principal Executive, Financial and Accounting Officer 1